Diabetic neuropathies are nerve damaging disorders associated with diabetes mellitus. These conditions are thought to result from a diabetic microvascular injury involving small blood vessels that supply nerves (vasa nervorum) in addition to macrovascular conditions that can accumulate in diabetic neuropathy.
This report contains market size and forecasts of Diabetic Neuropathy Drugs in Global, including the following market information:
Global Diabetic Neuropathy Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Diabetic Neuropathy Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Calcium Channel Alpha-2 Delta Ligand Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Diabetic Neuropathy Drugs include Pfizer, Novartis, Johnson & Johnson, Eli Lilly, GlaxoSmithKline, Boehringer Ingelheim, Teva Pharmaceutical, Daiichi Sankyo and Astellas Pharma. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Diabetic Neuropathy Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Diabetic Neuropathy Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Diabetic Neuropathy Drugs Market Segment Percentages, by Type, 2021 (%)
Calcium Channel Alpha-2 Delta Ligand
SNRIs and TCAs
Others
Global Diabetic Neuropathy Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Diabetic Neuropathy Drugs Market Segment Percentages, by Application, 2021 (%)
Hospitals
Drug Stores
Others
Global Diabetic Neuropathy Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Diabetic Neuropathy Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Diabetic Neuropathy Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Diabetic Neuropathy Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Novartis
Johnson & Johnson
Eli Lilly
GlaxoSmithKline
Boehringer Ingelheim
Teva Pharmaceutical
Daiichi Sankyo
Astellas Pharma